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Abstract  Emerging  concepts  in  the  pathophysiology  of  gastroesophageal  reﬂux  disease  (GERD)
and the  constant  technologic  advances  in  the  diagnosis  and  treatment  of  this  clinical  condition
make it  necessary  to  frequently  review  and  update  the  clinical  guidelines,  recommendations,
and ofﬁcial  statements  from  the  leading  academic  groups  worldwide.  The  Asociación  Mexicana
de Gastroenterología  (AMG),  aware  of  this  responsibility,  brought  together  national  experts  in
this ﬁeld  to  analyze  the  most  recent  scientiﬁc  evidence  and  formulate  a  series  of  practical  rec-
ommendations  to  guide  and  facilitate  the  diagnostic  process  and  efﬁcacious  treatment  of  these
patients.  The  document  includes  algorithms,  ﬁgures,  and  tables  for  convenient  consultation,
along with  opinions  on  GERD  management  in  sensitive  populations,  such  as  pregnant  women
and older  adults.
©  2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
 Please cite this article as: Huerta-Iga F, Bielsa-Fernández MV, Remes-Troche JM, Valdovinos-Díaz MA, Tamayo-de la Cuesta JL, en
epresentación del Grupo para el estudio de la ERGE 2015. Diagnóstico y tratamiento de la enfermedad por reﬂujo gastroesofágico:
ecomendaciones de la Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México. 2016;81:208--222.
 The recommendations for the diagnosis and treatment of GERD published in this article represent the ﬁnal result of national experts
n the theme after a complete and detailed review of the relevant and high quality scientiﬁc literature available. While it does not possess
he methodological rigor of a clinical guideline or a consensus, the principal aim of this document is to offer the physician a practical path
o making an accurate diagnosis and deciding on the best therapeutic option for the GERD patient through the responsible use of human
nd technologic resources, and at the same time, to increase treatment efﬁcacy and lower its cost.
∗ Corresponding author. Jefatura de Endoscopía y Fisiología Digestiva, Hospital Ángeles Torreón. Paseo del Tecnológico 909-350. Col.
esidencial Tecnológico. Torreón, Coahuila, Mexico. C.P. 27250. Tel. and Fax: +52 (871) 222-5411.
E-mail address: fhuertaiga@gmail.com (F. Huerta-Iga).
♦ The names of the 2015 GERD Study Group members are listed in the Appendix.
255-534X/© 2016 Asociacio´n Mexicana de Gastroenterolog´ıa. Published by Masson Doyma Me´xico S.A. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diagnóstico  y  tratamiento  de  la  enfermedad  por  reﬂujo  gastroesofágico:
recomendaciones  de  la  Asociación  Mexicana  de  Gastroenterología
Resumen  Los  nuevos  conceptos  en  la  ﬁsiopatología  de  la  enfermedad  por  reﬂujo  gastroe-
sofágico (ERGE)  y  los  constantes  avances  tecnológicos  aplicados  al  diagnóstico  y  el  tratamiento
de esta  condición  clínica  hacen  necesarias  la  revisión  frecuente  y  la  actualización  de  guías
clínicas,  recomendaciones  y  posturas  oﬁciales  de  los  principales  organismos  académicos  a  nivel
mundial. La  Asociación  Mexicana  de  Gastroenterología,  consciente  de  esta  responsabilidad,
reúne a  los  expertos  nacionales  de  este  tema  para  analizar  la  evidencia  cientíﬁca  más  reciente  y
construir  una  serie  de  recomendaciones  prácticas  para  orientar  y  facilitar  el  proceso  diagnóstico
y el  tratamiento  eﬁcaz  de  los  pacientes  afectados  por  esta  enfermedad.  Se  incluyen  algorit-
mos, diagramas  de  ﬂujo,  cuadros  y  tablas  que  concentran  estas  recomendaciones  y  se  agregan
opiniones sobre  el  manejo  de  la  ERGE  en  poblaciones  sensibles  como  las  mujeres  embarazadas
y las  personas  de  la  tercera  edad.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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bGeneralities, pathophysiology, and clinical
presentation
Deﬁnition  and  general  concept  of  gastroesophageal
reﬂux disease
GERD  is  a  result  of  the  ascent  of  the  gastric  or  gastroduo-
denal  content  above  the  gastroesophageal  junction,  which
causes  symptoms  and/or  esophageal  lesions  that  affect  the
health  and  quality  of  life  of  the  individuals  that  suffer  from
it.1,2
Classiﬁcation  and  deﬁnition  of  the  main
gastroesophageal  reﬂux  disease  phenotypes
The  most  widely  used  classiﬁcation  of  GERD,  worldwide,  is
the  Montreal  Classiﬁcation3 (Fig.  1).  It  divides  GERD  into
Esophageal
syndromes
Symptomatic
syndromes
Nonerosive
reflux disease
(NERD)
Esophagitis
Stricture
Barrett’s
esophagus
Adenocarcinoma
Thoracic pain
due to reflux
Syndromes with
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Figure  1  Montreal  Classiﬁcation  for  GERD.
Taken  from  Vakil  et  al.3.
t
t
d large  groups:  esophageal  syndromes  and  extra-esophageal
yndromes.  Esophageal  syndromes  are,  in  turn,  subdivided
nto  those  characterized  by  being  purely  symptomatic,  such
s  nonerosive  reﬂux  disease  (NERD)  and  noncardiac  chest
ain,  and  those  that  in  addition  to  symptoms,  present  with
esions  that  are  macroscopically  visible  at  conventional
ndoscopy.  Traditionally,  and  from  a  practical  perspective,
 phenotypic  varieties  of  GERD  are  recognized  that  can  be
iagnosed  through  endoscopy  alone:  NERD,  erosive  reﬂux
isease  (ERD),  and  Barrett’s  esophagus  (BE).  However,  care
ust  be  taken  to  rule  out  functional  heartburn  in  NERD
atients.  The  symptoms  are  the  common  denominator  in
ll  these  variants,  and  each  one  has  a  different  clinical
ehavior.Pharyngitis
Sinusitis
Idiopathic
pulmonary fibrosis
Recurrent otitis
media
Cough due to reflux
Laryngitis due
to reflux
Asthma due to reflux
Dental erosions due
to reflux
Extraesophageal
syndromes
Established
associations
Proposed
associations
The  extra-esophageal  syndromes  are  subdivided  into
hose  with  sufﬁcient  clinical  evidence  to  relate  the  symp-
om  to  GERD,  such  as  chronic  cough,  posterior  laryngitis,
ifﬁcult-to-control  asthma,  and  dental  erosions,  and  in
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Table  1  Worldwide  prevalence  of  heartburn  and/or  regur-
gitation  at  least  once  a  week.
Region  or  country  Heartburn  and/or  regurgitation
at least  once  a  week
The  United  States  18.1%-27.8%
Europe  8.8%-25.9%
The  Far  East  2.2%-7.8%
Australia  11.6%
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wArgentina  23.0%
Mexico  19.6%-40%
hose  in  which  it  has  not  been  possible  to  relate  the  symp-
om  to  GERD,  such  as  pharyngitis,  sinusitis,  recurrent  otitis
edia,  and  pulmonary  ﬁbrosis.
revalence  of  gastroesophageal  reﬂux  disease
ERD  is  a  frequent  disease,  but  its  prevalence  is  difﬁcult  to
stimate,  especially  when  taking  symptom  frequency  into
ccount.  Different  studies  on  the  topic  generally  speak  of
he  prevalence  of  symptoms  suggestive  of  the  disease,  but
ery  few  clearly  demonstrate  GERD.
Analyzing  only  the  studies  that  consider  the  presence  of
eartburn  or  regurgitation  once  a  week,  the  reported  preva-
ence  varies  from  18.1  to  27.8%  in  the  United  States,  from  8.8
o  25.9%  in  Europe,  from  2.2  to  7.8%  in  the  Far  East,  11.6%  in
ustralia,  23%  in  Argentina,  and  from  19.6  to  40%  in  Mexico
Table  1).  Based  on  the  results  from  a  recent  national  survey
SIGAME),4 it  was  found  that  in  an  open  Mexican  population,
ccording  to  the  Rome  III  criteria,  the  frequency  of  heart-
urn  or  regurgitation  at  least  once  a  week  is  12.1%  (95%  CI,
1.09  to  13.1),  it  is  1.2%  (95%  CI,  .09  to  1.3)  in  those  that
resent  with  symptoms  daily,  and  it  is  49.1%  (95%  CI,  47.5
o  50.6)  in  those  that  present  with  symptoms  at  least  once
 month  (Table  2).  That  study  concludes  that  GERD  is  a  dis-
ase  with  a  high  prevalence  in  Mexico,  with  regurgitation  as
he  main  symptom,  followed  by  heartburn  and  a  bitter  taste
n  the  mouth.  The  subjects  with  symptoms  of  GERD  were
igniﬁcantly  older.  A  multivariate  analysis  showed  that  the
reatest  prevalence  was  found  in  the  male  sex,  with  stud-
es  on  university  students  or  professionals,  and  that  they
elonged  to  medium-high  and  high  economic  strata.
The  international  DIGEST  study5 estimated  that  the
revalence  of  GERD  symptoms  is  7.7%,  with  heartburn  as
he  most  frequent  (13.5%)  of  the  digestive  symptom  group.
t  also  showed  that  regurgitation  represents  an  important
ercentage  (10.2%).
In  Latin  America,  there  are  very  few  reports  in  the  lit-
rature  on  the  prevalence  of  GERD.  A  systematic  review
Table  2  Prevalence  of  heartburn  and/or  regurgitation  in
Mexico  based  on  their  frequency.
Heartburn  and/or  regurgitation  in  Mexico  (SIGAME)
Daily  1.2%
Once a  week  12.1%
Once a  month  49.1%
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valuated  prevalence  studies  in  the  region  (a  total  of  8
tudies,  one  in  Argentina,  5  in  Brazil,  and  2  in  Mexico),
oncluding  that  there  was  a  3  to  11.9%  prevalence.6
ational  and  worldwide  incidence
here  is  very  little  information  on  GERD  incidence,  with  no
ational  reports  and  very  few  foreign  ones.  A  5%  incidence
f  reﬂux  esophagitis  in  endoscopies  carried  out  on  an  open
hinese  population  was  reported,7 along  with  a  22.5%  inci-
ence  in  patients  with  heartburn,  whereas  a  1.77  to  2.80%
ncidence  of  reﬂux  was  reported  in  Iran.8
isk  factors  and  susceptible  population
ome  of  the  most  important  risk  factors  for  developing  GERD
re:  heredity,  overweight,  central  obesity,  smoking,  alcohol,
nd  pregnancy.
The  above  should  not  be  confused  with  the  factors  that
avor  or  exacerbate  gastroesophageal  reﬂux  (GER),  such  as
ats,  chocolate,  coffee,  alcohol,  and  gastric  banding.  How-
ver,  evidence  is  poor  and  controversial  and  so  must  be
ndividualized  for  each  patient.9
Helicobacter  pylori  does  not  directly  participate  in  the
athophysiology  of  GERD  and  thus  its  eradication  should  not
e  considered  part  of  GERD  treatment.
athophysiology  of  gastroesophageal  reﬂux  disease
ERD  pathophysiology  is  multifactorial.  Its  main  patho-
hysiologic  mechanism  is  transient  lower  esophageal
phincter  relaxation  (TLESR),  deﬁned  as  a LES  relaxation
f  >  1  mmHg/s  lasting  at  least  10  s  and  a  pressure  nadir  of
 2  mmHg  in  the  absence  of  a  swallow  4  s before  and  2  s
fter  the  beginning  of  the  LES  relaxation.
Other  mechanisms  that  participate  in  GERD  are  the
sophageal  clearance  disorders,  whether  mechanic  (peri-
talsis  or  Earth’s  gravity)  or  chemical  (saliva),  antireﬂux
arrier  alterations  (hiatal  hernia,  reduced  LES  pressure),
elayed  gastric  emptying,  or  duodenal-gastric  reﬂux.10
The  extra-esophageal  pathophysiologic  manifestations
re  based  on  the  direct  acid  damage  to  the  pharyngeal
ucosa  and  possible  bronchial  microaspiration  episodes,  as
ell  as  esophageal  distension  with  a  vagovagal  reﬂex  that
roduces  bronchial  spasm  and  associated  symptomatology.
iagnosisymptoms
he  typical  GERD  symptoms  are  heartburn  and  regurgita-
ion.  The  presence  of  typical  symptoms  2  or  more  times  a
eek  in  a  young  patient  (under  50  years  of  age)  with  no
larm  symptoms  establishes  the  presumptive  diagnosis  of
ERD.  A  therapeutic  trial  with  a  proton  pump  inhibitor  (PPI)
s  recommended  for  these  patients.2,11,12
Gastroesophageal  reﬂux  disease  diagnosis  and  treatment  
Los Angeles Classification
≥ 1 mucosal break ≤ 5 mm not extending between folds Grade A
≥ 1 mucosal break  > 5 mm not extending between folds  Grade B
Grade C ≥ 1 mucosal break continuous between folds but involves  < 75% ofthe circumference of the esophagus
 
Grade D ≥ 1 mucosal break that involves at least 75% of the circumference ofthe esophagus
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bFigure  2  The  Los  Angeles  Classiﬁcation.
Taken  from  Lundell  et  al.  Gut  1999;45(2):172-180.
Therapeutic  trial
A  PPI  trial  can  be  utilized  to  diagnose  GERD  in  patients  that
have  typical  symptoms  with  no  red  ﬂags.  There  is  no  consen-
sus  as  to  the  type  of  PPI,  dose,  duration,  or  result  evaluation.
In  general,  a  double  PPI  dose  is  recommended  for  a  mini-
mum  of  2  weeks  and  is  considered  positive  when  symptom
improvement  is  above  50%.  Even  though  this  test  is  easy  to
perform  and  widely  available,  its  sensitivity  and  speciﬁcity
are  low.12--14
Symptom  questionnaires
Symptom  questionnaires  are  instruments  that  identify  GERD
patients.  The  ReQuest,  Carlsson-Dent,  and  RDQ  have  been
validated  in  Spanish.  They  are  frequently  used  in  research
studies,  but  their  usefulness  in  daily  practice  is  limited
because  of  sub-optimal  sensitivity  and  speciﬁcity.15--18
Conventional  endoscopy  and  biopsies
Endoscopy  should  not  be  routinely  used  as  a  screening  study
for  GERD  due  to  its  poor  diagnostic  sensitivity.
Endoscopy  is  useful  for  detecting  GERD  complications,
such  as  esophagitis  (Fig.  2),  stricture,  BE,  and  adenocarci-
noma.  Therefore,  it  is  indicated  in  cases  of  GERD  with  more
than  5  years  of  progression  or  refractory  GERD,  in  patients
with  alarm  symptoms  such  as  dysphagia,  gastrointestinal
bleeding,  chest  pain,  and  unintentional  weight  loss,  and  in
patients  with  risk  factors  for  BE  and  in  cases  of  suspected
eosinophilic  esophagitis.2,12,19
The  taking  of  biopsies  during  endoscopy  is  indicated
in  cases  with  lesions  suggestive  of  BE  and  suspicion  of
eosinophilic  esophagitis.  They  should  not  be  taken  to  conﬁrm
GERD  diagnosis.
Magnifying  endoscopy  and  the  use  of  optical  ﬁlters
Magnifying  endoscopy  with  conventional  or  electronic  chro-
moendoscopy  (NBI,  FICE,  i-Scan)  enables  the  identiﬁcation
of  microerosions  and  alterations  in  the  vascular  pattern  of
the  esophageal  mucosa  in  patients  with  NERD.  Confocal  laser
endomicroscopy  evaluates  esophageal  mucosal  histology  at
the  cellular  level  in  real  time  and  enables  directed  biopsies
to  be  performed  to  detect  dysplasia  in  BE.  These  techniques
are  not  recommended  in  the  routine  evaluation  of  GERD
patients.20--23
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sophagogram
sophagogram  is  not  useful  for  diagnosing  GERD.  It  is  indi-
ated  in  the  evaluation  of  esophageal  strictures,  large  hiatal
ernias,  and  suspicion  of  short  esophagus  in  patients  that  are
andidates  for  anti-reﬂux  surgery.24
sophageal  pH  monitoring  (pH  study)
he  ambulatory  24  to  48  h  measuring  of  esophageal  pH
pH  study)  is  indicated  in  patients  with  typical  or  extra-
sophageal  symptoms  of  GERD  and  negative  endoscopy  that
o  not  respond  to  PPI  therapy,  and  to  conﬁrm  the  pres-
nce  of  pathologic  reﬂux  in  patients  that  are  candidates  for
nti-reﬂux  surgery  with  no  evidence  of  esophageal  mucosal
esions  at  endoscopy.  Care  should  be  taken  to  suspend  acid-
locking  medications  at  least  7  days  before  the  study.  The
outine  performance  of  intragastric  pH  measurement  in  the
roximal  esophagus  or  the  hypopharynx  is  not  recommended
n  the  evaluation  of  GERD  patients.25
he  Bravo  system
he  wireless  system  (Bravo  capsule)  of  esophageal  pH  mea-
urement,  compared  with  pH  equipment  with  probes,  is
etter  tolerated  by  the  patient  and  has  greater  sensitivity
or  detecting  acid  reﬂux  and  establishing  the  association  of
ymptoms  with  reﬂux  episodes.  Its  limitations  are  cost  and
vailability,  chest  pain,  and  the  fact  that  it  does  not  detect
on-acid  reﬂux.26--28
sophageal  impedance-pH  monitoring
he  ambulatory  24  h  esophageal  impedance-pH  measure-
ent  is  indicated  in  cases  of  refractory  GERD  to  identify  the
ole  of  non-acid  reﬂux  in  persistent  symptoms  that  do  not
espond  to  PPIs.  It  can  detect  excessive  supragastric  burping
nd  rule  out  rumination  when  combined  with  high  resolution
anometry,  but  it  cannot  diagnose  biliary  reﬂux.12,29,30
The  indication  for  measuring  esophageal  reﬂux  with  or
ithout  PPI  depends  on  the  pre-test  probability  of  pre-
enting  with  GERD:
.  Patients  with  a  low  pre-test  probability  of  presenting
with  GERD,  that  is,  those  patients  with  PPI-refractory
symptoms,  extra-esophageal  manifestations,  negative
endoscopy,  or  those  patients  that  are  candidates  for  anti-
reﬂux  surgery  can  be  evaluated  through  conventional  pH
study,  impedance-pH  test,  or  the  Bravo  capsule  without
PPI  treatment.31
.  Patients  with  a  high  pre-test  probability  of  presenting
with  GERD,  that  is,  those  patients  with  typical  symp-
toms,  endoscopy  with  hiatal  hernia,  or  with  PPI  response
should  be  evaluated  through  an  impedance-pH  test  with
PPI  treatment.
ymptom  index  and  symptom  association
robability
he  indices  for  the  association  of  symptoms  with
eﬂux  episodes  (symptom  index  and  symptom  association
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robability) are  useful  for  classifying  patients  with  GERD
ccording  to  the  Rome  criteria.
Because  their  precision  depends  on  the  adequate  recor-
ing  of  symptoms  by  the  patient  and  on  the  percentage  of
ime  with  reﬂux,  these  indices  should  not  be  used  as  the
nly  criteria  for  indicating  anti-reﬂux  surgery.32,33
ilitec
he  ambulatory  measuring  of  duodenogastroesophageal
eﬂux  with  Bilitec  2000  is  of  little  clinical  usefulness  and
s  currently  unavailable.  Its  use  is  limited  to  research
tudies.34--35
sophageal  manometry
sophageal  manometry  is  not  useful  for  diagnosing  GERD.  It
hould  be  routinely  performed  in  the  preoperative  evalua-
ion  of  patients  that  are  candidates  for  anti-reﬂux  surgery
o  rule  out  severe  alterations  in  esophageal  motility  (acha-
asia,  scleroderma).  It  is  indicated  for  locating  the  LES  and
he  proper  placement  of  pH  electrodes.32,36
igh  resolution  and  impedance  manometry
igh  resolution  esophageal  manometry  is  superior  to  con-
entional  manometry  in  relation  to  diagnostic  performance
ecause  it  utilizes  a  standardized,  objective  measuring  sys-
em  that  enables  the  simultaneous  visualization  of  the
ontractility  of  the  entire  esophagus,  and  as  a  result,  con-
ractility  patterns  are  more  easily  recognized  and  have
reater  reproducibility.  It  is  very  useful  for  evaluating
ysphagia  after  anti-reﬂux  surgery.  When  combined  with
n  impedance  study,  it  can  distinguish  rumination  from
ERD-associated  regurgitation  and  it  detects  excessive
upragastric  burps  associated  with  GERD.37,38
ther  technologies  for  diagnosing
astroesophageal  reﬂux  disease
he  following  are  new  techniques  whose  clinical  usefulness
n  the  diagnostic  evaluation  of  patients  with  GERD  is  still
eing  studied:
a.  Impedance  measuring  of  the  esophageal  mucosa  distin-
guishes  patients  with  GERD  from  those  without  GERD,
with  achalasia,  and  with  eosinophilic  esophagitis.39
.  The  determination  of  pepsin  in  saliva  through  monoclonal
antibodies  is  a  noninvasive  method  that  distinguishes
patients  with  GERD  from  those  with  functional  heartburn
and  identiﬁes  patients  with  laryngopharyngeal  reﬂux.  Its
diagnostic  sensitivity  and  speciﬁcity  depends  on  the  lev-
els  of  pepsin  and  the  number  of  saliva  samples  analyzed
and  when  they  were  taken.  Two  samples  in  the  postpran-
dial  period  are  recommended.40
c.  The  pharyngeal  pH  measuring  system  (Restech)  is  a new
system  for  detecting  aerosolized  and  liquid  acid  in  the
hypopharynx  during  24  h.  It  is  poorly  correlated  with
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impedance-pH  monitoring  and  its  role  as  a  predictor  of
surgical  treatment  response  is  controversial.41
.  Hypopharyngeal  impedance-pH  monitoring  is  a  novel
technique  speciﬁcally  designed  for  detecting  reﬂux
episodes  in  the  proximal  esophagus  and  hypopharynx.  It
has  shown  advantages  in  the  detection  of  laryngopharyn-
geal  reﬂux  in  patients  with  bronchopulmonary  disorders,
but  its  usefulness  as  a  predictor  of  response  to  surgical
treatment  is  not  yet  clear.42
.  Impedance  planimetry  utilizing  an  endoscopic  functional
luminal  imaging  probe  (EndoFLIP)  measures  esophageal
distensibility  and  the  esophagogastric  junction.  Its  use-
fulness  in  GERD  diagnosis  and  in  the  calibration  of
fundoplication  during  anti-reﬂux  surgery  is  still  being
evaluated.43,44
edical treatment
reatment  aims
he  treatment  of  GERD  patients  should  be  individualized  and
riented  towards  the  clinical  presentation  of  the  disease  and
ymptom  intensity.
The  aim  in  relation  to  the  nonerosive  variant  with  typical
ymptoms  is  symptom  control,  and  in  the  erosive  variant,  is
rosion  cicatrization  and  the  prevention  of  complications.
In  patients  with  BE,  the  aim  is  to  prevent  progression  to
ysplasia  and  adenocarcinoma.
And  in  patients  with  atypical  GERD  (cough,  asthma,
aryngitis,  etc.),  the  aim  is  to  control  the  symptoms
nd  prevent  complications,  as  long  as  there  is  evidence
ssociating  laryngeal  symptoms  with  GERD  (see  Diagnosis
ection).
onpharmacologic  treatment
ifestyle  modiﬁcations
Lifestyle  modiﬁcations  and  dietary  recommendations
hould  be  individualized  for  each  patient.45,46 Evidence
hows  that  it  is  recommendable  to:
 Lose  weight,  in  overweight  and  obese  subjects47
 Stop  smoking45,46
 Reduce  alcohol  consumption45
 Raise  the  head  of  the  bed48,49
 Sleep  in  the  left  lateral  decubitus  position
 Avoid  abundant  food  intake  at  least  2  h  before  going
to  bed  at  night,  especially  if  the  subject  has  nocturnal
symptoms50
There  is  no  evidence  for  a general  recommendation  to
liminate  foods  that  can  apparently  trigger  reﬂux  symp-
oms,  such  as:  spicy  food,  citrus  fruit,  foods  with  a
igh  fat  content,  products  with  caffeine,  and  carbonated
everages.45 If  the  patient  ﬁnds  that  any  of  these  foods  are
ssociated  with  his  or  her  symptoms,  eliminating  them  from
he  diet  can  be  beneﬁcial.
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Table  3  Proton  pump  inhibitor  regimens  and  types  of  doses.
Proton  pump  inhibitor  Standard  dose  Double  dose  Divided  dosea
Conventional
Omeprazole  20  mg  30  min  before  breakfast  20  mg  30  min  before  breakfast
and  before  dinner
10  mg  30  min  before  breakfast
and  before  dinner
Lansoprazole  15  mg  30  min  before  breakfast  15  mg  30  min  before  breakfast
and  before  dinner
--
Rabeprazole  20  mg  30  min  before  breakfast  20  mg  30  min  before  breakfast
and  before  dinner
10  mg  30  min  before  breakfast
and  before  dinner
Pantoprazole  40  mg  30  min  before  breakfast  40  mg  30  min  before  breakfast
and  before  dinner
20  mg  30  min  before  breakfast
and  before  dinner
Esomeprazole  40  mg  30  min  before  breakfast 40  mg  30  min  before  breakfast
and  before  dinner
20  mg  30  min  before  breakfast
and  before  dinner
Dual delayed-release
Dexlansoprazole  30  mg  in  the  morning,
regardless  of  food  intake
60  mg  in  the  morning,
regardless  of  food  intake
--
Immediate  release
Omeprazole  +  HCO3  20  mg  +  1,100  mg  30  min  before
breakfast
40  mg  +  1,100  mg  30  min  before
breakfast
--
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Pharmacologic  treatment
Medications  used  in  GERD  treatment  are:  antacids,  algi-
nates,  sucralfate,  histamine2-receptor  antagonists  (H2RAs),
prokinetics,  PPIs,  and  TLESR  inhibitors.
Antacids  and  alginates
Antacids  and  alginates  are  recommended  for  symptom  relief
and  do  not  contribute  to  erosion  cicatrization  or  prevent
the  development  of  complications.51,52 There  is  no  evidence
supporting  their  chronic  use.
Histamine2-receptor  antagonists
H2RAs  should  not  be  used  as  ﬁrst-line  treatment  and  are
auxiliaries  in  PPI  management.53 They  can  be  used  in  cases  of
GERD  with  typical  and  sporadic  symptoms.  They  can  also  be
used  as  treatment  in  cases  of  NERD  if  they  produce  symptom
relief  and  in  cases  of  nocturnal  GERD  (together  with  a PPI  in
the  morning),  but  they  are  recommended  for  short  periods
since  tachyphylaxis  is  produced  in  7  days.54,55 They  are  also
indicated  in  GERD  in  the  context  of  PPI  hypersensitivity  or
side  effects.
Sucralfate
There  is  no  evidence  for  its  recommendation.12
Prokinetics
These  medications  should  not  be  used  as  the  sole  treatment
in  GERD  management.  When  symptoms  suggest  gastric  emp-
tying  alterations  (e.g.  overlap  with  dyspepsia),  prokinetics
can  be  used  in  combination  with  a  PPI.2,56,57It  is  important  to  be  aware  that  prokinetics  can
have  relevant  side  effects  that  should  be  watched  for,
such  as  hyperprolactinemia,  late  dyskinesia,  diarrhea,  and
headache.
d
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mse are presented
roton  pump  inhibitors
PIs  are  ﬁrst-choice  medications  for  the  treatment  of  GERD
n  all  its  clinical  forms,  given  that  they  provide  greater
nd  faster  symptom  relief,  as  well  as  higher  cicatriza-
ion  percentages,  compared  with  placebo,  antacids,  and
2RAs.51--55,58
There  are  currently  various  PPIs  (Table  3)  and  all  of
hem,  when  adequately  prescribed,  are  efﬁcacious.2,12,53
ven  though  studies  show  varying  rates  in  intragastric  pH
ontrol  and  symptom  response,  meta-analyses  have  shown
hat  effectiveness  among  the  different  PPIs  is  similar.59
It  is  important  to  instruct  patients  that  ‘‘conventional’’
PIs  should  be  taken  at  least  30  min  before  breakfast,
ecause  that  is  the  time  of  day  in  which  there  is  a
reater  quantity  of  active  pumps  in  the  parietal  cells.12
 dual  delayed-release  PPI,  dexlansoprazole,  has  recently
ecome  available.  In  pharmacokinetic  studies,  it  has  been
hown  to  maintain  adequate  therapeutic  levels,  regardless
f  food  intake,  which  facilitates  treatment  adherence.60
ome  studies  have  even  recommended  dexlansoprazole  use
s  management  therapy  in  patients  with  NERD  that  have
chieved  symptom  control  with  double  doses  of  conven-
ional  PPIs.61 However,  more  studies  are  needed  comparing
exlansoprazole  with  the  other  PPIs.  A  combination  of
meprazole  and  bicarbonate  with  no  enteric  coating  layer
s  also  available  in  Mexico  and  is  considered  a  drug  of
mmediate  release,  which  apparently  has  a faster  effect.
evertheless,  more  studies  with  respect  to  this  are  required.
ong-term  safety  of  proton  pump  inhibitors
n  general,  PPIs  are  considered  safe  and  adverse  effects
re  rare  (<  2%),  the  most  common  of  which  are:  nausea,
iarrhea,  headache,  insomnia,  and  anaphylaxis.62
In  regard  to  long-term  safety,  some  adverse  effects  have
een  described  in  the  last  few  years:  osteoporosis,63,64 vita-
in  deﬁciencies,65 hyperplastic  polyps,66 interaction  with
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edications  (clopidogrel),67,68 bacterial  overgrowth,  and
lostridium  difﬁcile  infection.69--71
Due  to  this,  numerous  meta-analyses  have  been  con-
ucted  with  controversial  results.  Nevertheless,  evidence
llows  the  following  recommendations  to  be  made:
 Chronic  PPI  use,  especially  in  subjects  over  65  years  of
age,  is  a  risk  factor  for  C.  difﬁcile  and  other  enteric  infec-
tions,  such  as  Salmonella  and  Campylobacter.69
 Chronic  PPI  use  should  not  be  considered  the  sole  risk
factor  for  osteoporosis.64
 Even  though  short-term  PPI  use  is  associated  with  the
development  of  community-acquired  pneumonia  in  a
high-risk  population,  it  is  no  greater  than  that  associated
with  H2RA  use.70,71
 Concomitant  PPI  use  with  clopidogrel  does  not  increase
the  risk  for  cardiovascular  events.67,68
ransient  lower  esophageal  sphincter  relaxation
nhibitors
t  present,  baclofen  has  shown  greater  usefulness  for  reduc-
ng  TLESRs.  This  drug  is  not  available  in  Mexico,  but  there
s  moderate  evidence  that  the  use  of  this  GABA- agonist
educes  transient  sphincter  relaxations,  thus  reducing  reﬂux
pisodes  (acid  and  non-acid).72,73 It  is  recommended  as  an
djuvant  to  PPIs  in  patients  with  failed  response  to  these,
lthough  its  high  incidence  of  adverse  effects  must  be  taken
nto  account,  such  as  headache,  dizziness,  and  constipation,
imiting  its  clinical  use.
reatment  strategies  and  duration
onerosive  reﬂux  disease  treatment
he  standard  PPI  dose  is  recommended  in  these  cases
Table  3)  for  a  period  of  4  weeks  (ﬁg.  3).2,12,58 If  symptom
ontrol  is  achieved,  the  medication  should  be  suspended  and
einitiated  in  case  of  relapse.74,75
If  there  is  recurrence,  the  following  maintenance  regi-
ens  with  PPIs  can  be  employed:
.  Continuous:  uninterruptedly  use  the  minimum  PPI  dose
that  provides  symptom  control.73
.  On-demand:  use  the  standard  dose  every  time  the  patient
presents  with  symptoms  and  suspend  it  when  they  have
been  controlled.72
.  Intermittent:  use  the  standard  dose  for  deﬁned  periods
of  at  least  2-4  weeks  every  time  there  is  symptom
recurrence.73
Another  maintenance  option  is  to  switch  from  a  PPI  to  a
2RA,  using  the  latter  for  short  periods  and  only  in  the  case
f  mild  or  intermittent  symptoms.76
If  response  is  partial  or  nonexistent  with  the  initial
PI  dose,  the  following  situations  should  be  investigated
ﬁg.  3):77
 adequate  drug  prescription  and  administration
 product  quality
 treatment  adherence
If  none  of  the  abovementioned  applies,  then  doubling
he  dose  (see  Table  3),  changing  the  PPI,  or  dividing  the
i
e
e
nF.  Huerta-Iga  et  al.
ose  during  the  day  (if  there  are  nocturnal  symptoms)  are
trategies  that  should  be  tried.78--82 If  there  is  no  symptom
ontrol  despite  taking  these  measures,  the  patient  should
e  re-evaluated  (see  Diagnosis)  and  categorized  as  having
PI  failure  or  refractory  GERD.
rosive  reﬂux  disease  treatment
n  cases  of  ERD,  8-week  PPI  treatment  achieves  symp-
om  control  and  endoscopic  cure  of  lesions  in  more  than
0%  of  the  cases.2,12,51 Duration  depends  on  lesion  severity
Fig.  4).
In  cases  of  esophagitis  C  and  D,  experts  recommend
epeat  endoscopy  study  at  8  to  12  weeks  from  the  begin-
ing  of  treatment  to  rule  out  BE  that  has  been  hidden  by
nﬂammation.  Due  to  the  fact  that  in  C  and  D  cases  recur-
ence  is  nearly  100%  at  6  months,  endoscopic  evaluation  is
ecommended  upon  treatment  completion.77,83 Maintenance
reatment  should  be  individualized  in  those  cases  and  evalu-
ted  in  accordance  with  patient  expectations  and  his  or  her
nvironment.  These  are  options  that  can  include  continuous
PI  treatment  and  even  the  possibility  of  surgical  treatment
see  Surgical  treatment  section).
reatment  of  atypical  gastroesophageal  reﬂux  disease
xtraesophageal  manifestations  with  typical  symptoms:  in
atients  with  extra-esophageal  symptoms  (laryngitis,  cough,
nd  asthma)  that  also  suffer  from  typical  symptoms  (heart-
urn  and/or  regurgitation),  beginning  therapy  with  a  PPI
rial  (double  dose  for  8 to  12  weeks)  is  indicated.12 In  these
ases  the  response  to  atypical  symptom  is  unpredictable.  If
here  is  good  response,  treatment  should  be  prolonged  and
vidence  suggests  that  the  double  dose  should  be  prescribed
or  periods  of  up  to  2-3  months.84 If  there  is  no  improve-
ent  in  3  months,  the  symptoms  are  most  likely  secondary
o  another  cause  and  diagnosis  should  be  reconsidered.
No  evidence  supports  the  use  of  prokinetics  in  patients
ith  laryngopharyngeal  reﬂux,  whether  combined  with
 PPI  or  as  monotherapy.  A  recent  systematic  review,
ncluding  only  4  high  quality  studies  to  be  analyzed,  deter-
ined  that  there  was  a  high  risk  for  bias  due  to  the
eterogeneity  with  which  laryngopharyngeal  reﬂux  was
eﬁned.
In  patients  that  present  only  with  supposed  atypical
anifestations  of  GERD,  a  monitoring  test,  such  as  an
mpedance-pH  study,  is  recommendable  before  administer-
ng  PPI  treatment.85 If  there  is  no  abnormal  esophageal
xposure  to  acid  or  positive  symptom  association,  GERD  is
uled  out  as  the  cause  of  extra-esophageal  symptoms  and
he  patient  should  be  re-evaluated.
reatment  of  erosive  reﬂux  disease  in  cases  of  proton
ump  inhibitor  failure  (refractory  gastroesophageal
eﬂux  disease)
atients  categorized  as  having  PPI  failure  or  refractory  GERD
ccording  to  Figure  3  should  be  re-evaluated  to  rule  out
ther  causes  that  could  explain  their  symptoms.
If  the  patients  persist  with  typical  symptoms,  endoscopy
s  recommendable  to  rule  out  entities  that  include
osinophilic  esophagitis  and  organic  dyspepsia,  among  oth-
rs,  and  thus  reconsider  treatment.12,86 If  endoscopy  is
egative,  manometry  should  be  carried  out  and  then
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NERD
PPI in standard dose
(4 weeks)
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Figure  3  Nonerosive  reﬂux  disease  management.  In  the  proposed  maintenance  regimens,  the  red  ovals  indicate  symptom  reap-
pearance. For  example,  in  the  on-demand  regimen,  once  symptoms  appear,  treatment  is  given  for  the  length  of  time  the  patient  has
symptoms (white  rectangles);  in  the  intermittent  regimen,  treatment  duration  can  vary  from  2  to  4  weeks,  even  when  symptoms
n
i
a
o
tare no  longer  present.
PPI:  proton  pump  inhibitor.
an  esophageal  impedance-pH  monitoring  study  while  the
patient  is  taking  a  PPI.12,85 Based  on  this  study,  there  are
3  possibilities  (Fig.  5):
1.  Persistence  of  abnormal  esophageal  exposure  to  acid:
in  these  cases  a  change  of  PPI,  dividing  or  increasing
the  dose,  or  adding  a  nocturnal  dose  of  H2RA  can  be
recommended.
2.  Esophageal  exposure  to  normal  acid,  but  positive  symp-
tom  association  with  non-acid  reﬂux:  baclofen  (not
available  in  Mexico)  is  indicated  in  these  cases,  and
although  still  controversial,  some  studies  suggest  surgical
treatment  could  be  beneﬁcial.72,73,87,88
3.  Negative  study  (with  no  evidence  of  acid  or  non-acid
reﬂux):  GERD  is  ruled  out  as  the  cause  of  symptoms  in
r
t
b
othese  cases  and  they  are  classiﬁed  as  functional  heart-
burn.  Visceral  analgesics  and  other  neuromodulators,
such  as  amitriptyline,  desipramine,  citalopram,  and  ven-
lafaxine  are  indicated.89
If  the  patients  persist  with  atypical  symptoms  and  there  is
o  improvement,  they  should  be  reevaluated  by  a  specialist
n  otorhinolaryngology,  pneumology,  allergology,  or  psychi-
try,  depending  on  the  case.  If  a  pH  study  was  not  carried
ut  during  the  initial  evaluation  of  the  case,  it  is  important
o  perform  one  without  treatment,  and  depending  on  the
esult,  reconsider  the  treatment.  If  the  pH  study  is  nega-
ive,  GERD  can  be  ruled  out  as  the  cause  of  the  symptoms,
ut  if  the  study  is  positive,  then  the  PPI  should  be  changed
r  the  dose  divided  or  increased.
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8-week treatment
Suspend
Grades C and D
Consider:
Relapse
Consider
maintenance
• New endoscopyue
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   therapy
• Surgery in young people
Figure  4  Erosive  reﬂux  disease  management.
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possible,  the  sample  should  be  sent  to  an  expert  patholo-reatment of special cases
arrett’s  esophagus
eﬁnition  of  Barrett’s  esophagus
E  is  a  premalignant  lesion  of  the  esophagus  that  is  deﬁned
s  the  replacement  of  the  squamous  epithelium  of  the  dis-
al  portion  of  the  esophagus  with  columnar  epithelium  of
ny  length,  suspected  by  its  endoscopic  appearance  and
orroborated  by  a  histopathology  study  reporting  complete
ntestinal  metaplasia.90,91
revalence  of  and  risk  factors  for  Barrett’s  esophagus
ERD  is  the  most  important  pathogenic  factor  for  the  devel-
pment  of  BE  and  its  prevalence  in  GERD  patients  varies
rom  10  to  15%.  Additional  factors  such  as  race,  age,  male
ex,  smoking,  obesity,  and  hiatal  hernia,  among  others,  also
lay  a  signiﬁcant  role.92
The  intentional  search  for  BE  through  endoscopy  is  justi-
ed  in  subjects  that  have  various  risk  factors:  men  above  50
ears  of  age,  a  history  of  GER  symptoms  of  long  progression
more  than  5  years),  especially  if  the  patient  presents  with
besity  or  overweight.91,93
g
i
(Just  having  symptoms  of  GER  is  not  sufﬁcient  justiﬁca-
ion  for  performing  endoscopy  in  the  search  for  BE.  Despite
he  fact  that  a  considerable  number  of  the  adult  population
omplains  of  reﬂux  symptoms,  only  a small  number  of  them
evelop  BE.  The  prevalence  of  BE  reported  in  the  general
opulation  varies  from  1.2  to  1.6%.94,95
reatment  and  surveillance  of  Barrett’s  esophagus
deally,  cases  of  BE  should  be  treated  by  a specialist  and
referably  at  a referral  center.  Despite  the  fact  that  at
resent  there  is  not  enough  evidence  to  support  medical
r  surgical  treatment  as  a  strategy  for  preventing  the  neo-
lastic  progression  of  BE,  PPIs  should  be  used,  preferably  in
 continuous  regimen,  to  control  reﬂux  symptoms.
Endoscopic  surveillance  at  established  intervals  in  accor-
ance  with  the  presence  and  grade  of  dysplasia  is
ecommended  in  all  patients  with  BE.  The  diagnosis  of  dys-
lasia  should  be  conﬁrmed  by  a  second  pathologist  or,  ifist.  Intense  PPI  treatment  between  follow-up  endoscopies
s  highly  recommendable.
The  recommended  strategies  for  endoscopic  vigilance  are
Table  4):
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PPI failure
Atypical symptoms
(cough, laryngitis, asthma)
Reevaluate ORL,
pneumology, allergy
Specific treatment
pH impedance without 
PPI
pH impedance with
PPI
Acid reflux persists Non-acid reflux
Typical symptoms
Endoscopy
Normal
Normal
NormalNormal Acid reflux
Double PPI dose, change
PPI, fraction PPI dose
Visceral
analgesics
Baclofen,
surgery ?
Double
PPI dose, change PPI,
fraction PPI dose,
add H2RA
EoE, Dyspepsia,
Organic disease. 
onis
t
a
vFigure  5  Management  of  PPI  failure  or  refractory  GERD.
EoE: eosinophilic  esophagitis;  H2RA:  histamine-2  receptor  antag
•  EB  with  no  dysplasia:  endoscopic  surveillance  with  biopsy
is  recommended  in  the  ﬁrst  year.  If  the  patient  contin-
ues  with  no  dysplasia,  endoscopy  with  biopsy  should  be
performed  every  5  years.
•  BE  with  low-grade  dysplasia:  endoscopy  with  biopsy
directed  at  the  site  of  dysplasia  every  6  months.  After
2  consecutive  years  with  no  dysplasia,  the  patient  can
return  to  the  endoscopy  regimen  for  no  dysplasia.•  BE  with  high-grade  dysplasia:  endoscopic  or  surgical
resection  based  on  the  availability  of  resources  and
trained  endoscopists  or  expert  surgeons.  If  the  patient
is  not  a  candidate  for  or  does  not  accept  resection,
p
(
i
Table  4  Recommendations  for  Barrett’s  esophagus  surveillance.
Society  High-grade  dysplasia  Low-grade
AGA94 Deﬁnitive  treatment  EMR/RFA
or  surveillance  every  3months
Repeat  EG
there  is  d
annual  sur
ASGEa Deﬁnitive  treatment  EGD  every
2  years,  th
ACG98 Deﬁnitive  treatment  Repeat  EG
every  yea
EGD: esophagogastroduodenoscopy; EMR: endoscopic mucosal resectio
a Taken from Hirota et al. ASGE Guideline: the role of endoscopy in t
Gastrointest Endosc 2006; 63(4):570-580.ts;  ORL:  Otorhinolaryngology;  PPI:  proton  pump  inhibitor.
endoscopy  with  biopsy  should  be  performed  every  3
months.
The  current  endoscopic  BE  treatment  recommenda-
ion  is  endoscopic  mucosal  resection  of  the  visible  lesions
nd/or  radiofrequency  ablation  of  the  residual  BE  to  pre-
ent  metachronic  lesions  or  recurrent  neoplasia,  as  well  as
atient  follow-up  with  endoscopic  surveillance.
Endoscopic  ablation  therapy  with  liquid  nitrogen  in  spray
cryotherapy)  has  been  shown  to  be  efﬁcacious  in  small  stud-
es  and  has  been  proposed  as  alternative  therapy  for  treating
 dysplasia  No  dysplasia
D  in  6  months.  If
ysplasia:  RFA  or
veillance
EGD  every  3-5  years.  Select
high-risk  patients  (RFA)
 6  months  for
en  every  year
2  EGDs  during  ﬁrst  year;  then
every  3  years
D  at  6  months;  then
r  until  regression
2  EGDs  during  ﬁrst  year;  then
every  3  years
n; RFA: radiofrequency ablation.
he surveillance of premalignant conditions of the upper GI tract.
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igh-grade  dysplasia  in  BE  patients,  but  is  not  presently  rec-
mmended  as  ﬁrst-line  therapy.
ndoscopic  management  of  gastroesophageal
eﬂux  disease
ndoscopic  management  of  uncomplicated
astroesophageal  reﬂux  disease
oday,  the  2  clinically  available  methods  for  managing
ncomplicated  GERD  are  radiofrequency  ablation  (Stretta)
nd  endoluminal  fundoplication  with  EsophyX.  The  effec-
iveness  of  these  methods  has  not  been  well  conﬁrmed  and
hey  should  not  be  recommended  in  all  patients.
ndoscopic  management  of  complicated
astroesophageal  reﬂux  disease  (esophageal  stricture)
a.  The  initial  treatment  of  choice  for  managing  esophageal
strictures  due  to  reﬂux  is  endoscopic  dilation  with  plugs
or  balloon.
b.  There  is  no  evidence  of  a  clear  advantage  in  using
plug  dilation  or  balloon  dilation  for  the  management  of
esophageal  strictures  caused  by  reﬂux.
c.  The  management  of  refractory  or  complex  strictures  can
include  the  use  of  fully  covered  self-expandable  metal
stents  or  endoscopic  radial  incision  of  the  stricture.
.  Patients  that  receive  endoscopic  treatment  of
esophageal  stricture  due  to  reﬂux  should  also  receive
double  dose,  continuous  PPI  treatment.
urgical  management  of  gastroesophageal  reﬂux
isease
efore  considering  surgery,  it  is  indispensible  to  have
bjective  documentation  of  GERD,  whether  demonstrating
ucosal  damage  through  endoscopy  (esophagitis  of  at  least
rade  B  of  the  Los  Angeles  Classiﬁcation,  stricture  or  BE
qual  to  or  greater  than  3  cm  in  length)  or  through  24  h
sophageal  pH  study  in  the  absence  of  epithelial  alterations.
herefore,  all  patients  that  are  candidates  for  surgery
hould  undergo  preoperative  endoscopy  and,  in  some  cases,
 pH  study  to  conﬁrm  the  diagnosis.  It  may  be  necessary
o  carry  out  an  esophagogram  in  certain  patients  and  ide-
lly  all  should  undergo  a  preoperative  manometry  test  (see
iagnosis  section).
ndications  for  surgical  treatment  of  gastroesophageal
eﬂux  disease
atients  with  an  objective  diagnosis  of  GERD  can  be  consid-
red  for  surgical  treatment  in  the  following  cases:
.  Patients  that  present  with  a  reduced  quality  of  life,  per-
sistent  symptoms  that  cause  problems,  and/or  disease
progression  despite  adequate  PPI  therapy.96,97
.  Patients  with  good  PPI  response,  PPI-dependent,  and
with  acceptable  quality  of  life  can  be  considered  for
surgery  if  they  wish  to  have  it.  The  patient  must  be
informed  as  to  the  potential  side  effects  and  possible
risks  of  the  surgery.98,99
.  Anti-reﬂux  surgery  can  improve  quality  of  life  in  certain
patients  with  NERD.100,101
o
I
t
sF.  Huerta-Iga  et  al.
.  Patients  with  extra-esophageal  symptoms  that  have  pos-
itive  symptom  correlation  and  good  PPI  response  can
beneﬁt  from  anti-reﬂux  surgery.102--105
.  Patients  with  GERD  and  obesity  can  beneﬁt  more  from
bariatric  surgery,  such  as  gastric  bypass,  than  from  anti-
reﬂux  surgery.  Indications  are  based  on  body  mass  index
and  bariatric  surgery  criteria.106,107
f.  Patients  with  large  hiatal  hernia  (>  5  cm).
.  Patients  with  aspiration  pneumonia
Novel  devices,  such  as  the  LINX  and  EndoStim,  are  cur-
ently  being  evaluated  and  have  shown  promising  results.
owever,  more  comparative,  long-term  studies  are  required
o  determine  their  place  in  GERD  treatment.108--111
reatment  of  gastroesophageal  reﬂux  disease  during
regnancy
eartburn  is  a  frequent  symptom  during  pregnancy  and  its
ain  etiologic  factor  is  the  hormonal  effect  of  progesterone.
omplications  of  GERD  during  pregnancy  are  not  common
nd  therefore  the  routine  performance  of  diagnostic  studies,
uch  as  endoscopy,  is  not  indicated.
Treatment  should  be  carried  out  in  ascending  order,
eginning  with  lifestyle  and  dietary  modiﬁcations.  First-line
rug  management  should  be  based  on  antacids  and  sucral-
ate.  If  symptoms  persist,  an  H2RA  can  be  included.  However,
izatidine  should  not  be  used,  given  that  there  have  been
eports  of  spontaneous  abortions  and  congenital  malforma-
ions  in  laboratory  animals,  leaving  PPI  use  for  untreatable
r  complicated  symptoms  and  preferably  from  the  second
rimester  of  gestation.  The  FDA  considers  all  PPIs  class  B
rugs,  except  omeprazole,  which  is  considered  class  C.112--114
n  general,  prokinetics  are  not  recommended  for  GERD  treat-
ent,  and  so  their  use  during  pregnancy  should  be  oriented
oward  the  management  of  difﬁcult-to-control  nausea  and
omiting,  speciﬁcally  with  metoclopramide,  categorized  as
 class  B drug  by  the  FDA.115
reatment  of  gastroesophageal  reﬂux  in  the  elderly
he  aims  of  GERD  treatment  in  persons  above  65  years  of
ge  are  essentially  the  same  as  those  in  patients  below  that
ge.  Prevalence  is  difﬁcult  to  establish,  given  that  there  are
ew  studies  speciﬁcally  conducted  on  this  age  group  and  the
oncomitant  diseases  and  other  treatments  hinder  both  the
iagnosis  and  treatment  of  these  patients.  In  general,  fre-
uency  and  symptom  intensity  in  relation  to  heartburn  and
egurgitation  are  lower  in  patients  above  the  age  of  65,  but
omplications  of  GERD,  such  as  bleeding,  stricture,  or  BE  as
rimary  manifestations  of  the  disease  are  frequently  found.
PPIs  are  the  ﬁrst-line  treatment  in  any  of  the  clinical
resentations  of  GERD  in  this  group  of  patients.  The  rec-
mmended  doses  are  the  same  and  it  should  be  kept  in
ind  that  treatment  will  very  likely  be  continuous.  Spe-
ial  care  must  be  taken  in  relation  to  PPIs  that  compete
ith  other  medications  that  have  hepatic  metabolism  at  the
450  cytochrome  level,  such  as  warfarin,  phenytoin,  the-
phylline,  benzodiazepines,  and  calcium  channel  blockers.
t  appears  that  omeprazole  and  esomeprazole  are  the  PPIs
hat  compete  the  most  for  the  hepatic  metabolism  site  and
o  they  should  be  used  as  little  as  possible.116
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